Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1063-1069

  Boku, Narikazu ^a   Yamamoto, Seiichiro ^b   Fukuda, Haruhiko ^b   Shirao, Kuniaki ^c   Doi, Toshihiko ^c   Sawaki, Akira ^d   Koizumi, Wasaburo ^e   Saito, Hiroshi ^f   Yamaguchi, Kensei ^g   Takiuchi, Hiroya ^h   Nasu, Junichiro ⁱ   Ohtsu, Atsushi ^c  

^a SHIZUOKA CANCER CENTER   (Japan)

^b Centre for Cancer Control   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e KITASATO UNIVERSITY HOSPITAL   (Japan)

^f Yamagata Prefectural Central Hospital   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h OSAKA MEDICAL COLLEGE   (Japan)

ⁱ National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71249128928     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70259-1     Document Type: Article

References (34)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Murad A.M., Santiago F.F., Petroianu A., Rocha P.R., Rodrigues M.A., and Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
3. Glimelius B., Hoffman K., Haglund U., Nyrén O., and Sjödén P.O. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5 (1994) 189-190
4. Pyrhönen S., Kuitunen T., Nyandoto P., and Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
5. Cullinan S.A., Moertel C.G., Fleming T.R., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 253 (1985) 2061-2067
6. Wils J.A., Klein H.O., Wagener D.J., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer-a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9 (1991) 827-831
7. Kelsen D., Atiq O.T., Saltz L., et al. FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer. J Clin Oncol 10 (1992) 541-548
8. Cocconi G., Bella M., Zironi S., et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12 (1994) 2687-2693
9. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
10. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (2000) 2648-2657
11. Kim N.K., Park Y.S., Heo D.S., et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71 (1993) 3813-3818
12. Cullinan S.A., Moertel C.G., Wieand H.S., et al. Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol 12 (1994) 412-416
13. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (2003) 54-59
14. Boku N., Ohtsu A., Shimada Y., et al. A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17 (1999) 319-323
15. Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., and Taguchi T. Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34 (1998) 1715-1720
16. Koizumi W., Kurihara M., Nakano S., and Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58 (2000) 191-197
17. Pocock S.J., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115
18. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
19. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (2008) 215-221
20. Imamura H, IIishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). 2008 Gastrointestinal Cancers Symposium; Orlando, FL, USA; Jan 25-27, 2008. Abstract 5.
21. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20 (2009) 666-673
22. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (2008) 36-46
23. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006) 2903-2909
24. Hoff P.M., Saad E.D., Ajani J.A., et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9 (2003) 134-142
25. Ajani J.A., Faust J., Ikeda K., et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23 (2005) 6957-6965
26. Shirao K., Hoff P.M., Ohtsu A., et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22 (2004) 3466-3474
27. Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. 2008 ASCO annual meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 4533.
28. Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. 2009 ASCO annual meeting; Orlando, FL, USA; May 29-June 2, 2009. Abstract 4511.
29. Ajani J.A., Baker J., Pisters P.W., et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94 (2002) 641-646
30. Nagashima F., Boku N., Ohtsu A., et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 35 (2005) 714-719
31. Yamada Y, Yamamoto S, Ohtsu A, et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. 2009 ASCO annual meeting; Orlando, FL, USA; May 29-June 2, 2009. Abstract 4535.
32. Dank M., Zaluski J., Barone C., et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19 (2008) 1450-1457
33. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006) 4991-4997
34. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (2008) 1435-1442